Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adverse myocardial and vascular side effects of immune checkpoint inhibitors: a prospective multimodal cardiovascular assessment.
Mirabel M, Eslami A, Thibault C, Oudard S, Mousseaux E, Wahbi K, Fabre E, Terrier B, Marijon E, Villefaillot A, Fayol A, Dragon-Durey MA, Le Louet AL, Bruno RM, Soulat G, Hulot JS. Mirabel M, et al. Among authors: fabre e. Clin Res Cardiol. 2024 Aug;113(8):1263-1273. doi: 10.1007/s00392-024-02462-x. Epub 2024 May 28. Clin Res Cardiol. 2024. PMID: 38806821
Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N, Zonta E, Didelot A, Combe P, Thibault C, Gibault L, Lours C, Rozenholc Y, Taly V, Laurent-Puig P, Blons H, Fabre E. Pécuchet N, et al. Among authors: fabre e. PLoS Med. 2016 Dec 27;13(12):e1002199. doi: 10.1371/journal.pmed.1002199. eCollection 2016 Dec. PLoS Med. 2016. PMID: 28027313 Free PMC article.
Safety and efficacy of immunotherapy according to the age threshold of 80 years.
Mebarki S, Pamoukdjian F, Pierro M, Poisson J, Baldini C, Widad Lahlou, Taieb J, Fabre E, Canoui-Poitrine F, Oudard S, Paillaud E. Mebarki S, et al. Among authors: fabre e. Bull Cancer. 2023 May;110(5):570-580. doi: 10.1016/j.bulcan.2023.02.010. Epub 2023 Mar 7. Bull Cancer. 2023. PMID: 36894391 Free article. Review.
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Daban A, Gonnin C, Phan L, Saldmann A, Granier C, Lillo-Lelouet A, Le Beller C, Pouchot J, Weiss L, Tartour E, Fabre E, Medioni J, Oudard S, Vano YA, Dragon-Durey MA, Simonaggio A. Daban A, et al. Among authors: fabre e. Oncoimmunology. 2023 May 11;12(1):2204754. doi: 10.1080/2162402X.2023.2204754. eCollection 2023. Oncoimmunology. 2023. PMID: 37187974 Free PMC article.
Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study.
Oudard S, Thiam R, Fournier LS, Medioni J, Lamuraglia M, Scotte F, Fabre E, Kim D, Kpamegan E, Panneerselvam A, Cuenod CA. Oudard S, et al. Among authors: fabre e. Eur J Cancer. 2012 Jul;48(10):1512-8. doi: 10.1016/j.ejca.2012.01.027. Epub 2012 Feb 16. Eur J Cancer. 2012. PMID: 22342553 Clinical Trial.
The Tumor Antigen Cyclin B1 Hosts Multiple CD4 T Cell Epitopes Differently Recognized by Pre-Existing Naive and Memory Cells in Both Healthy and Cancer Donors.
Chevaleyre C, Benhamouda N, Favry E, Fabre E, Mhoumadi A, Nozach H, Marcon E, Cosler G, Vinatier E, Oudard S, Hans S, Le Pimpec-Barthes F, Bats AS, Castelli FA, Tartour E, Maillère B. Chevaleyre C, et al. Among authors: fabre e. J Immunol. 2015 Aug 15;195(4):1891-901. doi: 10.4049/jimmunol.1402548. Epub 2015 Jul 1. J Immunol. 2015. PMID: 26136431
247 results